Non-Small Cell Lung Cancer
Arrivent Biopharma Inc. focuses on non-small cell lung cancer across locally advanced and metastatic settings, with studies centered on tumors driven by EGFR-related alterations.
- Locally advanced NSCLC
- Metastatic NSCLC
- Non-squamous lung cancer
The sponsor’s research activity includes treatment settings where targeted therapy is being evaluated against established systemic options in lung cancer care.
EGFR Mutation-Driven Disease
Its clinical programme places strong emphasis on epidermal growth factor receptor alterations, including uncommon PACC mutations and activating EGFR exon 20 insertion variants.
- EGFR PACC uncommon mutations
- EGFR exon 20 insertion mutations
- Activating EGFR mutations
These studies reflect a clear interest in mutation-defined lung cancer populations that require more specific therapeutic approaches.
HER2-Driven Lung Cancer
Arrivent Biopharma also studies NSCLC with activating HER2 kinase domain mutations, extending its oncology portfolio beyond EGFR-mutated disease.
- HER2 kinase domain mutations
- Mutation-selected NSCLC
- Targeted thoracic oncology
This area highlights interest in molecularly defined lung cancers linked to distinct oncogenic drivers.
Targeted Anticancer Therapy
The sponsor’s trials examine EGFR inhibitor and HER2-directed treatment strategies in comparison with standard cancer therapies such as platinum-based chemotherapy.
- EGFR inhibitor therapy
- HER2-directed therapy
- Platinum-based chemotherapy
Research activity is concentrated on antitumor treatment choices for patients with biomarker-defined lung cancer.
